Medicus Pharma Ltd. SEC filings MDCX
Medicus Pharma Ltd. has 343 filings in SEC EDGAR's recent list, going back to Oct 13, 2023. Its latest annual report, Form ARS, was filed on May 4, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 425 | Form 425 | Nov 4, 2026 | — |
| DEF 14A | Proxy statement | Oct 30, 2026 | Dec 2, 2026 |
| 424B3 | Prospectus | Oct 26, 2026 | — |
| 8-K |
Current report
Listing notice, Other events
|
Oct 23, 2026 | Oct 20, 2026 |
| PRE 14A | Preliminary proxy statement | Oct 19, 2026 | Dec 2, 2026 |
| 424B3 | Prospectus | Oct 16, 2026 | — |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Oct 16, 2026 | Oct 12, 2026 |
| 424B3 | Prospectus | Oct 7, 2026 | — |
| 8-K |
Current report
Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 424B3 | Prospectus | Sep 14, 2026 | — |
| 8-K |
Current report
Agreement ended
|
Sep 14, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 11, 2026 | Sep 4, 2026 |
| 424B3 | Prospectus | Sep 3, 2026 | — |
| 8-K |
Current report
Material agreement
|
Sep 3, 2026 | Sep 2, 2026 |
| 424B3 | Prospectus | Aug 13, 2026 | — |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 424B3 | Prospectus | Jun 4, 2026 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
| 424B3 | Prospectus | May 28, 2026 | — |
| 8-K |
Current report
Material agreement, New debt, Listing notice
|
May 27, 2026 | May 20, 2026 |
| 424B3 | Prospectus | May 14, 2026 | — |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | May 4, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | May 4, 2026 | Jun 3, 2026 |
| 424B3 | Prospectus | Apr 30, 2026 | — |
| 10-K/A | Amended annual report | Apr 29, 2026 | Dec 31, 2025 |
| 424B3 | Prospectus | Apr 27, 2026 | — |
| 8-K |
Current report
Material agreement, Listing notice
|
Apr 24, 2026 | Apr 21, 2026 |
| 424B3 | Prospectus | Apr 23, 2026 | — |
| PRE 14A | Preliminary proxy statement | Apr 21, 2026 | Jun 3, 2026 |
| EFFECT | Filing | Mar 27, 2026 | — |
| EFFECT | Filing | Mar 27, 2026 | — |
| EFFECT | Filing | Mar 27, 2026 | — |
| POS AM | Form pos am | Mar 25, 2026 | — |
| POS AM | Form pos am | Mar 25, 2026 | — |
| POS AM | Form pos am | Mar 25, 2026 | — |
| 424B3 | Prospectus | Mar 25, 2026 | — |
| 424B3 | Prospectus | Mar 25, 2026 | — |
| 424B3 | Prospectus | Mar 25, 2026 | — |
| 424B3 | Prospectus | Mar 25, 2026 | — |
| 10-K | Annual report | Mar 25, 2026 | Dec 31, 2025 |
| 424B3 | Prospectus | Mar 6, 2026 | — |
| 424B3 | Prospectus | Mar 6, 2026 | — |
| 424B3 | Prospectus | Mar 6, 2026 | — |
| 424B3 | Prospectus | Mar 6, 2026 | — |
| 253G2 | Form 253g2 | Mar 6, 2026 | — |
| 8-K |
Current report
Unregistered share sale
|
Mar 6, 2026 | Mar 5, 2026 |
| EFFECT | Filing | Feb 4, 2026 | — |
| CORRESP | Letter to the SEC | Jan 30, 2026 | — |
| S-3 | Shelf registration | Jan 30, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2026 | — |
| DRS | Filing | Jan 12, 2026 | — |
| 424B5 | Prospectus supplement | Jan 2, 2026 | — |
| EFFECT | Filing | Dec 31, 2025 | — |
| 424B3 | Prospectus | Dec 30, 2025 | — |
| 424B3 | Prospectus | Dec 30, 2025 | — |
| 424B3 | Prospectus | Dec 30, 2025 | — |
| 424B3 | Prospectus | Dec 30, 2025 | — |
| 253G2 | Form 253g2 | Dec 30, 2025 | — |
| 424B3 | Prospectus | Dec 30, 2025 | — |
| 424B3 | Prospectus | Dec 30, 2025 | — |
| 8-K |
Current report
Material agreement
|
Dec 30, 2025 | Dec 29, 2025 |
| S-3 | Shelf registration | Dec 30, 2025 | — |
| CORRESP | Letter to the SEC | Dec 29, 2025 | — |
| DRS | Filing | Dec 10, 2025 | — |
| 253G2 | Form 253g2 | Dec 8, 2025 | — |
| 424B3 | Prospectus | Dec 8, 2025 | — |
| 424B3 | Prospectus | Dec 8, 2025 | — |
| 424B3 | Prospectus | Dec 8, 2025 | — |
| 424B3 | Prospectus | Dec 8, 2025 | — |
| 424B3 | Prospectus | Dec 8, 2025 | — |
| 424B3 | Prospectus | Dec 8, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Dec 8, 2025 | Dec 5, 2025 |
| 424B3 | Prospectus | Dec 5, 2025 | — |
| EFFECT | Filing | Dec 4, 2025 | — |
| CORRESP | Letter to the SEC | Dec 2, 2025 | — |
| 253G2 | Form 253g2 | Dec 1, 2025 | — |
| 424B3 | Prospectus | Dec 1, 2025 | — |
| 424B3 | Prospectus | Dec 1, 2025 | — |
| 424B3 | Prospectus | Dec 1, 2025 | — |
| 424B3 | Prospectus | Dec 1, 2025 | — |
| 424B3 | Prospectus | Dec 1, 2025 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 1, 2025 | Nov 28, 2025 |
| S-1 | Registration statement | Nov 19, 2025 | — |
| 424B3 | Prospectus | Nov 17, 2025 | — |
| 424B3 | Prospectus | Nov 17, 2025 | — |
| 424B3 | Prospectus | Nov 17, 2025 | — |
| 424B3 | Prospectus | Nov 17, 2025 | — |
| 424B3 | Prospectus | Nov 17, 2025 | — |
| 253G2 | Form 253g2 | Nov 17, 2025 | — |
| EFFECT | Filing | Nov 14, 2025 | — |
| EFFECT | Filing | Nov 14, 2025 | — |
| 8-K |
Current report
Other events
|
Nov 14, 2025 | Nov 14, 2025 |
| S-8 | Employee stock plan registration | Nov 14, 2025 | — |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 424B3 | Prospectus | Oct 17, 2025 | — |
| 424B3 | Prospectus | Oct 17, 2025 | — |
| 253G2 | Form 253g2 | Oct 17, 2025 | — |
| 424B3 | Prospectus | Oct 17, 2025 | — |
| 8-K |
Current report
Unregistered share sale
|
Oct 17, 2025 | Oct 16, 2025 |
| S-1 | Registration statement | Sep 29, 2025 | — |
| S-1 | Registration statement | Sep 29, 2025 | — |
| DRS | Filing | Sep 19, 2025 | — |
| 424B3 | Prospectus | Sep 18, 2025 | — |
| 424B3 | Prospectus | Sep 18, 2025 | — |
| 253G2 | Form 253g2 | Sep 18, 2025 | — |
| 424B3 | Prospectus | Sep 18, 2025 | — |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Sep 18, 2025 | Sep 17, 2025 |
| 424B3 | Prospectus | Sep 15, 2025 | — |
| 424B3 | Prospectus | Sep 15, 2025 | — |
| 253G2 | Form 253g2 | Sep 15, 2025 | — |
| 424B3 | Prospectus | Sep 15, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Sep 12, 2025 | Sep 12, 2025 |
| DRS | Filing | Sep 11, 2025 | — |
| 424B3 | Prospectus | Sep 2, 2025 | — |
| 424B3 | Prospectus | Sep 2, 2025 | — |
| 424B3 | Prospectus | Sep 2, 2025 | — |
| 253G2 | Form 253g2 | Sep 2, 2025 | — |
| 8-K |
Current report
Acquisition or sale of assets, Unregistered share sale, Officer or director change, Other events
|
Sep 2, 2025 | Aug 29, 2025 |
| 424B3 | Prospectus | Aug 22, 2025 | — |
| 424B3 | Prospectus | Aug 22, 2025 | — |
| 253G2 | Form 253g2 | Aug 22, 2025 | — |
| 424B3 | Prospectus | Aug 22, 2025 | — |
| 8-K |
Current report
Unregistered share sale, Other events
|
Aug 22, 2025 | Aug 21, 2025 |
| 424B3 | Prospectus | Aug 12, 2025 | — |
| 424B3 | Prospectus | Aug 12, 2025 | — |
| 253G2 | Form 253g2 | Aug 12, 2025 | — |
| 424B3 | Prospectus | Aug 12, 2025 | — |
| 10-Q | Quarterly report | Aug 11, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Other events
|
Aug 4, 2025 | Aug 4, 2025 |
| 8-K |
Current report
Other events
|
Jul 30, 2025 | Jul 29, 2025 |
| 424B3 | Prospectus | Jul 23, 2025 | — |
| 424B3 | Prospectus | Jul 23, 2025 | — |
| 253G2 | Form 253g2 | Jul 23, 2025 | — |
| 424B3 | Prospectus | Jul 23, 2025 | — |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jul 23, 2025 | Jul 22, 2025 |
| 424B3 | Prospectus | Jul 14, 2025 | — |
| 424B3 | Prospectus | Jul 14, 2025 | — |
| 424B3 | Prospectus | Jul 14, 2025 | — |
| 253G2 | Form 253g2 | Jul 14, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jul 14, 2025 | Jul 14, 2025 |
| 424B3 | Prospectus | Jul 3, 2025 | — |
| 424B3 | Prospectus | Jul 3, 2025 | — |
| 253G2 | Form 253g2 | Jul 3, 2025 | — |
| 424B3 | Prospectus | Jul 3, 2025 | — |
| 8-K/A | Amended current report | Jul 3, 2025 | Jun 29, 2025 |
| UPLOAD | Letter from the SEC | Jul 1, 2025 | — |
| ARS | Annual report to shareholders | Jun 30, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Jun 30, 2025 | Jul 22, 2025 |
| 424B3 | Prospectus | Jun 30, 2025 | — |
| 424B3 | Prospectus | Jun 30, 2025 | — |
| 253G2 | Form 253g2 | Jun 30, 2025 | — |
| 424B3 | Prospectus | Jun 30, 2025 | — |
| 8-K |
Current report
Material agreement, Other events
|
Jun 30, 2025 | Jun 29, 2025 |
| 253G2 | Form 253g2 | Jun 24, 2025 | — |
| 424B3 | Prospectus | Jun 24, 2025 | — |
| 424B3 | Prospectus | Jun 24, 2025 | — |
| 424B3 | Prospectus | Jun 24, 2025 | — |
| CORRESP | Letter to the SEC | Jun 23, 2025 | — |
| PRER14A | Form prer14a | Jun 23, 2025 | — |
| 8-K |
Current report
Officer or director change, Other events
|
Jun 23, 2025 | Jun 23, 2025 |
| 424B3 | Prospectus | Jun 20, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 20, 2025 | — |
| 424B3 | Prospectus | Jun 20, 2025 | — |
| 253G2 | Form 253g2 | Jun 20, 2025 | — |
| 424B3 | Prospectus | Jun 20, 2025 | — |
| 8-K |
Current report
Material agreement, New debt
|
Jun 20, 2025 | Jun 17, 2025 |
| PRE 14A | Preliminary proxy statement | Jun 13, 2025 | Jul 22, 2025 |
| 424B3 | Prospectus | Jun 6, 2025 | — |
| 424B3 | Prospectus | Jun 6, 2025 | — |
| 253G2 | Form 253g2 | Jun 6, 2025 | — |
| 424B3 | Prospectus | Jun 6, 2025 | — |
| 8-K |
Current report
Auditor change
|
Jun 5, 2025 | Jun 3, 2025 |
| 424B3 | Prospectus | Jun 3, 2025 | — |
| 424B3 | Prospectus | Jun 3, 2025 | — |
| 424B3 | Prospectus | Jun 3, 2025 | — |
| 253G2 | Form 253g2 | Jun 3, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jun 2, 2025 | May 29, 2025 |
| 424B3 | Prospectus | May 30, 2025 | — |
| 424B4 | Prospectus | May 30, 2025 | — |
| EFFECT | Filing | May 29, 2025 | — |
| EFFECT | Filing | May 29, 2025 | — |
| CORRESP | Letter to the SEC | May 28, 2025 | — |
| CORRESP | Letter to the SEC | May 28, 2025 | — |
| S-1 | Registration statement | May 27, 2025 | — |
| CORRESP | Letter to the SEC | May 27, 2025 | — |
| S-1 | Registration statement | May 27, 2025 | — |
| 253G2 | Form 253g2 | May 13, 2025 | — |
| 424B3 | Prospectus | May 13, 2025 | — |
| 10-Q | Quarterly report | May 12, 2025 | Mar 31, 2025 |
| UPLOAD | Letter from the SEC | May 5, 2025 | — |
| 424B3 | Prospectus | May 5, 2025 | — |
| 253G2 | Form 253g2 | May 5, 2025 | — |
| 8-K |
Current report
Material agreement, New debt
|
May 5, 2025 | May 2, 2025 |
| DRS | Filing | May 1, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 30, 2025 | — |
| 10-K/A | Amended annual report | Apr 30, 2025 | Dec 31, 2024 |
| 253G2 | Form 253g2 | Apr 28, 2025 | — |
| 424B3 | Prospectus | Apr 28, 2025 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MDCX (Nasdaq), MDCXW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ontario, Canada
- Headquarters
- W. Conshohocken, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1997296
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.